(Q35206362)

7 August 2017

1 reference

title

Alemtuzumab therapy in B-cell lymphoproliferative disorders (English)

1 reference

7 August 2017

2

Peter Hillmen

0 references

author name string

Paul Moreton

series ordinal

1

1 reference

7 August 2017

publication date

1 August 2003

1 reference

7 August 2017

1 reference

7 August 2017

volume

30

1 reference

7 August 2017

issue

4

1 reference

7 August 2017

page(s)

493-501

1 reference

Biological and Clinical Implications of Lymphocyte Hybridomas: Tumor Therapy with Monoclonal Antibodies

7 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900253-7

7 January 2021

Reactivity of rat monoclonal antibody CAMPATH-1 with human leukaemia cells and its possible application for autologous bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900253-7

7 January 2021

REMISSION INDUCTION IN NON-HODGKIN LYMPHOMA WITH RESHAPED HUMAN MONOCLONAL ANTIBODY CAMPATH-1H

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900253-7

7 January 2021

Anti-globulin responses to rat and humanized CAMPATH-1 monoclonal antibody used to treat transplant rejection

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900253-7

7 January 2021

Characterization of the CAMPATH-1 (CDw52) antigen: biochemical analysis and cDNA cloning reveal an unusually small peptide backbone

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900253-7

7 January 2021

The CD52 antigen and development of the CAMPATH antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900253-7

7 January 2021

The CAMPATH-1 antigen (CDw52)

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900253-7

7 January 2021

The CD45 tyrosine phosphatase regulates Campath-1H (CD52)-induced TCR-dependent signal transduction in human T cells

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900253-7

7 January 2021

Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900253-7

7 January 2021

In vivo 'Purging' of residual disease in CLL with Campath-1H

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900253-7

7 January 2021

Humanized CD52 monoclonal antibody campath-1H as first-line treatment in chronic lymphocytic leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900253-7

7 January 2021

Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL).

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900253-7

7 January 2021

Alemtuzumab in relapsed or refractory chronic lymphocytic leukemia and prolymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900253-7

7 January 2021

Subcutaneous CAMPATH-1H in fludarabine-resistant/relapsed chronic lymphocytic and B-prolymphocytic leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900253-7

7 January 2021

Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900253-7

7 January 2021

Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900253-7

7 January 2021

Monoclonal antibody therapy with CAMPATH-1H in patients with relapsed high- and low-grade non-Hodgkin's lymphomas: a multicenter phase I/II study

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900253-7

7 January 2021

CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: a phase II multicenter study. European Study Group of CAMPATH-1H Treatment in Low-Grade Non-Hodgkin's Lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900253-7

7 January 2021

A phase II multicenter study of CAMPATH-1H antibody in previously treated patients with nonbulky non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900253-7

7 January 2021

Campath-1H-induced complete remission of chronic lymphocytic leukemia despite p53 gene mutation and resistance to chemotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900253-7

7 January 2021

CD52 expression in mantle cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900253-7

7 January 2021

Immunohistochemical analysis of CDw52 antigen expression in non-Hodgkin's lymphomas

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900253-7

7 January 2021

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900253-7

7 January 2021

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900253-7

7 January 2021

Rituximab dose-escalation trial in chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900253-7

7 January 2021

Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900253-7

7 January 2021

Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900253-7

7 January 2021

Campath-1H and fludarabine in combination are highly active in refractory chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900253-7

7 January 2021

Mechanism of first-dose cytokine-release syndrome by CAMPATH 1-H: involvement of CD16 (FcgammaRIII) and CD11a/CD18 (LFA-1) on NK cells

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900253-7

7 January 2021

Transient increase in symptoms associated with cytokine release in patients with multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900253-7

7 January 2021

Frequency and type of serious infections in fludarabine-refractory B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma: implications for clinical trials in this patient population

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900253-7

7 January 2021

Immunosuppressive toxicity of CAMPATH1H monoclonal antibody in the treatment of patients with recurrent low grade lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900253-7

7 January 2021

Levels of expression of CD52 in normal and leukemic B and T cells: correlation with in vivo therapeutic responses to Campath-1H

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900253-7

7 January 2021

Cytomegalovirus viremia during Campath-1H therapy for relapsed and refractory chronic lymphocytic leukemia and prolymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900253-7

7 January 2021

Fatal adenovirus infection during alemtuzumab (anti-CD52 monoclonal antibody) treatment of a patient with fludarabine-refractory B-cell chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900253-7

7 January 2021

Importance of antigen specificity for complement-mediated lysis by monoclonal antibodies.

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900253-7

7 January 2021

Chronic B cell malignancies and bone marrow microenvironment

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900253-7

7 January 2021

Campath-1G causes rapid depletion of circulating host dendritic cells (DCs) before allogeneic transplantation but does not delay donor DC reconstitution

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900253-7

7 January 2021

Quantitation of minimal disease levels in chronic lymphocytic leukemia using a sensitive flow cytometric assay improves the prediction of outcome and can be used to optimize therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900253-7

7 January 2021

A novel nested-PCR strategy for the detection of rearranged immunoglobulin heavy-chain genes in B cell tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0093-7754%2803%2900253-7

7 January 2021

10.1016/S0093-7754(03)00253-7

Identifiers

DOI

1 reference

7 August 2017

1 reference